Therapeutic Targeting of checkpoint Receptors within the DnAM1 Axis

被引：35

作者：

Alteber, Zoya ^{[1
]}

Kotturi, Maya F. ^{[2
]}

Whelan, Sarah ^{[2
]}

Ganguly, Sudipto ^{[3
]}

Weyl, Emmanuel ^{[1
]}

Pardoll, Drew M. ^{[3
]}

Hunter, John ^{[2
]}

Ophir, Eran ^{[1
]}

机构：

[1] Compugen Ltd, Holon, Israel

[2] Compugen USA Inc, San Francisco, CA USA

[3] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA

来源：

CANCER DISCOVERY | 2021年 / 11卷 / 05期

关键词：

COINHIBITORY MOLECULES; CELL-ADHESION; CUTTING EDGE; OPEN-LABEL; PVR CD155; T-CELLS; TIGIT; CD226; ANTITUMOR; CANCER;

D O I：

10.1158/2159-8290.CD-20-1248

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapeutic antibodies targeting the CTLA4/PD-1 pathways have revolutionized cancer immunotherapy by eliciting durable remission in patients with cancer. However, relapse following early response, attributable to primary and adaptive resistance, is frequently observed. Additional immunomodulatory pathways are being studied in patients with primary or acquired resistance to CTLA4 or PD-1 blockade. The DNAM1 axis is a potent coregulator of innate and adaptive immunity whose other components include the immunoglobulin receptors TIGIT, PVRIG, and CD96, and their nectin and nectin-like ligands. We review the basic biology and therapeutic relevance of this family, which has begun to show promise in cancer clinical trials. Significance: Recent studies have outlined the immuno-oncologic ascendancy of coinhibitory receptors in the DNAM1 axis such as TIGIT and PVRIG and, to a lesser extent, CD96. Biological elucidation backed by ongoing clinical trials of single-agent therapy directed against TIGIT or PVRIG is beginning to provide the rationale for testing combination regimens of DNAM1 axis blockers in conjunction with anti-PD-1/PD-L1 agents.

引用

页码：1040 / 1051

页数：12

共 99 条

[1]

[Anonymous], 2018, J IMMUNOTHER CANCER

[2] Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sezary syndrome [J].

Anzengruber, Florian ;

Ignatova, Desislava ;

Schlaepfer, Tanja ;

Chang, Yun-Tsan ;

French, Lars E. ;

Pascolo, Steve ;

Contassot, Emmanuel ;

Bobrowicz, Malgorzata ;

Hoetzenecker, Wolfram ;

Guenova, Emmanuella .

LEUKEMIA & LYMPHOMA, 2019, 60 (08) :1899-1907

[3] Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy [J].

Blake, Stephen J. ;

Stannard, Kimberley ;

Liu, Jing ;

Allen, Stacey ;

Yong, Michelle C. R. ;

Mittal, Deepak ;

Aguilera, Amelia Roman ;

Miles, John J. ;

Lutzky, Viviana P. ;

de Andrade, Lucas Ferrari ;

Martinet, Ludovic ;

Colonna, Marco ;

Takeda, Kazuyoshi ;

Kuehnel, Florian ;

Gurlevik, Engin ;

Bernhardt, Guenter ;

Teng, Michele W. L. ;

Smyth, Mark J. .

CANCER DISCOVERY, 2016, 6 (04) :446-459

[4] Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [J].

Borate, Uma ;

Esteve, Jordi ;

Porkka, Kimmo ;

Knapper, Steve ;

Vey, Norbert ;

Scholl, Sebastian ;

Garcia-Manero, Guillermo ;

Wermke, Martin ;

Janssen, Jeroen ;

Traer, Elie ;

Chua, Chong Chyn ;

Narayan, Rupa ;

Tovar, Natalia ;

Kontro, Mika ;

Ottmann, Oliver ;

Sun, Haiying ;

Longmire, Tyler ;

Szpakowski, Sebastian ;

Liao, Serena ;

Patel, Anuradha ;

Rinne, Mikael L. ;

Brunner, Andrew ;

Wei, Andrew H. .

BLOOD, 2019, 134

[5] Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule [J].

Bottino, C ;

Castriconi, R ;

Pende, D ;

Rivera, P ;

Nanni, M ;

Carnemolla, B ;

Cantoni, C ;

Grassi, J ;

Marcenaro, S ;

Reymond, N ;

Vitale, M ;

Moretta, L ;

Lopez, M ;

Moretta, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (04) :557-567

[6] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[8] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[9] CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells [J].

Braun, Matthias ;

Aguilera, Amelia Roman ;

Sundarrajan, Ashmitha ;

Corvino, Dillon ;

Stannard, Kimberley ;

Krumeich, Sophie ;

Das, Indrajit ;

Lima, Luize G. ;

Guzman, Lizeth G. Meza ;

Li, Kunlun ;

Li, Rui ;

Salim, Nazhifah ;

Jorge, Maria Villancanas ;

Ham, Sunyoung ;

Kelly, Gabrielle ;

Vari, Frank ;

Lepletier, Ailin ;

Raghavendra, Ashwini ;

Pearson, Sally ;

Madore, Jason ;

Jacquelin, Sebastien ;

Effern, Maike ;

Quine, Brodie ;

Koufariotis, Lambros T. ;

Casey, Mika ;

Nakamura, Kyohei ;

Seo, Eun Y. ;

Holzel, Michael ;

Geyer, Matthias ;

Kristiansen, Glen ;

Taheri, Touraj ;

Ahern, Elizabeth ;

Hughes, Brett G. M. ;

Wilmott, James S. ;

Long, Georgina V. ;

Scolyer, Richard A. ;

Batstone, Martin D. ;

Landsberg, Jennifer ;

Dietrich, Dimo ;

Pop, Oltin T. ;

Flatz, Lukas ;

Dougall, William C. ;

Veillette, Andre ;

Nicholson, Sandra E. ;

Moller, Andreas ;

Johnston, Robert J. ;

Martinet, Ludovic ;

Smyth, Mark J. ;

Bald, Tobias .

IMMUNITY, 2020, 53 (04) :805-+

[10] A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma [J].

Brignone, Chrystelle ;

Escudier, Bernard ;

Grygar, Caroline ;

Marcu, Manon ;

Triebel, Frederic .

CLINICAL CANCER RESEARCH, 2009, 15 (19) :6225-6231

← 1 2 3 4 5 6 7 8 9 10 →